Busy Period Ahead For CYTR, NBY Put On Notice, SRNE Surges On Cynviloq Deal

(RTTNews) - CytRx Corp. (CYTR) expects to complete enrollment in the ongoing pivotal global phase 3 clinical trial of Aldoxorubicin as a second-line treatment for soft tissue sarcoma in the first quarter of 2016, and report progression free survival data in second half of 2016.

Erollment in the ongoing phase 1b clinical trial with a combination of Aldoxorubicin and ifosfamide/mesna as first-line treatment for advanced sarcomas and in the phase 1b clinical trial with a combination of Aldoxorubicin and Gemcitabine in metastatic solid tumors are scheduled for completion in the second half of 2015.

A phase 2b clinical trial of Aldoxorubicin in relapsed/refractory small cell lung cancer is also underway, and is expected to complete enrollment in the first quarter of 2016, with progression free survival data expected by the second half of 2016.

CYTR closed Friday's trading at $3.70, down 15.72%.

NovaBay Pharmaceuticals Inc. (NBY) has received a noncompliance notice from NYSE MKT as the company's stockholders equity, as of December 31, 2014, is below the listing requirements.

In order to maintain its listing, NovaBay Pharmaceuticals is required to submit a plan of compliance by May 28, 2015, addressing how it intends to regain compliance within 18 months, or by November 28, 2016.

NBY closed Friday's trading at $0.65, up 2.94%.

Sorrento Therapeutics Inc. (SRNE) has acquired exclusive distribution rights to Cynviloq in South America from South Korean based-Samyang Biopharmaceuticals. The drug is marketed in some Asian countries for breast, lung, and ovarian cancer.

In the U.S., Cynviloq is being developed under the abbreviated 505(b)(2) regulatory pathway.

SRNE closed Friday's trading at $10.35, up 14.75%.